DDInter1174 DDInter255
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953.
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Methotrexate {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Busulfan
Methotrexate {u} (Compound) downregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Methotrexate {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is upregulated by {v} (Compound) Busulfan
Methotrexate {u} (Compound) downregulates {v} (Gene) EBNA1BP2
EBNA1BP2 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Methotrexate {u} (Compound) upregulates {v} (Gene) TNIP1
TNIP1 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Methotrexate {u} (Compound) causes {v} (Side Effect) Hyperuricaemia
Hyperuricaemia {u} (Side Effect) is caused by {v} (Compound) Busulfan
Methotrexate {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Busulfan
Methotrexate {u} (Compound) downregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) regulates {v} (Gene) MAMLD1
MAMLD1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Methotrexate {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is regulated by {v} (Gene) TBXA2R
TBXA2R {u} (Gene) is upregulated by {v} (Compound) Busulfan
Methotrexate {u} (Compound) downregulates {v} (Gene) EBNA1BP2
EBNA1BP2 {u} (Gene) interacts with {v} (Gene) TEX10
TEX10 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Methotrexate (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Busulfan (Compound)
Methotrexate (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene) is upregulated by Busulfan (Compound)
Methotrexate (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Busulfan (Compound)
Methotrexate (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is downregulated by Busulfan (Compound)
Methotrexate (Compound) upregulates TNIP1 (Gene) and TNIP1 (Gene) is downregulated by Busulfan (Compound)
Methotrexate (Compound) causes Hyperuricaemia (Side Effect) and Hyperuricaemia (Side Effect) is caused by Busulfan (Compound)
Methotrexate (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with GSTM1 (Gene) and GSTM1 (Gene) is bound by Busulfan (Compound)
Methotrexate (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene) regulates MAMLD1 (Gene) and MAMLD1 (Gene) is upregulated by Busulfan (Compound)
Methotrexate (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is regulated by TBXA2R (Gene) and TBXA2R (Gene) is upregulated by Busulfan (Compound)
Methotrexate (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) interacts with TEX10 (Gene) and TEX10 (Gene) is upregulated by Busulfan (Compound)